Company Overview

Daré Bioscience, Inc. is a biopharmaceutical company focused on the development of innovative products for women’s health, addressing contraception, sexual health, vaginal health, and hormone-related conditions. The company operates within the biotechnology and pharmaceutical development industries, primarily advancing drug candidates through clinical development and regulatory approval rather than commercial-scale manufacturing. Daré’s business model centers on identifying unmet needs in women’s health and developing differentiated, often first-in-category, product candidates.

The company’s primary revenue drivers to date have consisted of collaboration revenue, licensing arrangements, and grant funding, as Daré does not yet have an FDA-approved product generating recurring commercial sales. Daré is positioned as a women’s-health–focused development platform with a strategy of advancing multiple product candidates in parallel while leveraging partnerships for later-stage development and commercialization. The company traces its origins to its 2016 merger with Microchips Biotech, Inc., after which it rebranded as Daré Bioscience and shifted its strategic focus exclusively to women’s health therapeutics.

Business Operations

Daré Bioscience operates as a single reporting segment focused on women’s health product development, encompassing research, clinical development, regulatory strategy, and partner collaboration. Its pipeline has included product candidates targeting contraception (such as hormone-free and novel delivery approaches), vaginal infections, and female sexual health disorders. The company generates operating revenue primarily through strategic collaborations, option agreements, and government or foundation grants, while most operating expenses relate to research and development activities.

Operations are primarily U.S.-based, with clinical trials conducted domestically and, in some cases, internationally through contract research organizations. Daré controls intellectual property related to its proprietary formulations and delivery technologies while relying on third parties for manufacturing, clinical trial execution, and certain development functions. The company has entered into partnerships and licensing arrangements with pharmaceutical and biotechnology companies to advance specific assets, while retaining ownership of its broader pipeline. Information on certain development programs has changed over time, and in some cases public disclosures provide limited detail; where this occurs, data is inconclusive based on available public sources.

Strategic Position & Investments

Daré’s strategic direction emphasizes building a diversified women’s health pipeline and advancing assets to value-inflection points such as proof-of-concept or late-stage clinical data before seeking commercialization partners. Growth initiatives have included selective acquisitions of intellectual property, in-licensing of product candidates, and continued investment in clinical development programs addressing underserved indications in women’s health.

The company has made notable investments in hormone-free and novel contraceptive technologies and in therapies addressing conditions with limited existing treatment options. Daré has also maintained a strategy of forming partnerships with larger pharmaceutical companies to offset development risk and capital requirements. Subsidiaries and portfolio structures have evolved over time, and while Daré has referenced multiple development-stage assets in public filings, not all programs have progressed uniformly; where progress or ownership is unclear, data is inconclusive based on available public sources.

Geographic Footprint

Daré Bioscience is headquartered in the United States, with its principal executive offices in California. The company’s operational footprint is primarily domestic, reflecting its focus on U.S. regulatory approval pathways and clinical development infrastructure. However, Daré’s market focus is global, as many of its product candidates are intended for broad international applicability in women’s health.

International influence is primarily exercised through global clinical research vendors, manufacturing partners, and potential commercialization partners rather than through owned facilities or foreign subsidiaries. Daré has indicated that future commercialization strategies may include partnerships targeting Europe, Asia, and other international markets, though specific regional commercialization plans remain dependent on clinical and regulatory outcomes.

Leadership & Governance

Daré Bioscience is led by an executive team with experience in pharmaceutical development, regulatory strategy, and women’s health commercialization. The leadership philosophy emphasizes scientific rigor, capital efficiency, and partnering as a means to advance multiple product candidates simultaneously while managing development risk.

Key executives include:

• Sabrina Martucci Johnson – President and Chief Executive Officer
• David McNab – Chief Financial Officer
• John Biddell – Chief Operating Officer
• Stanley Lapidus – Chairman of the Board

The board and management team collectively provide oversight of corporate strategy, capital allocation, and governance, with a focus on advancing Daré’s mission to improve outcomes in women’s health. Some historical executive roles and board compositions have changed over time; where discrepancies exist across public disclosures, data is inconclusive based on available public sources.